Correction To: Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma: Final Update of the Pivotal ERIVANCE BCC Study

BMC Cancer - United Kingdom
doi 10.1186/s12885-019-5568-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma

Dermatology and Therapy
Dermatology
2020English

Lack of Response to Vismodegib in a Patient With Advanced Basal Cell Carcinoma: A Case Report

Journal of Clinical & Experimental Oncology
2017English

Vismodegib and Orbital Excision for Treating Locally Advanced Basal Cell Carcinoma

International Medical Case Reports Journal
Medicine
2018English

035 Experiences With Smo Antagonist Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2017English

233 Cohort Study of High Frequency Basal Cell Carcinoma (BCC) Patients in Denmark

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

533 Pembrolizumab With or Without Vismodegib for Advanced Basal Cell Carcinoma: An Investigator-Initiated, Proof-Of-Concept Study

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Vismodegib for Periocular and Orbital Basal Cell Carcinoma

JAMA Ophthalmology
Ophthalmology
2013English

Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2018English

Vismodegib for Giant, Locally Advanced, Basal Cell Carcinoma and Its Complex Position in Clinical Practice

JAAD Case Reports
Dermatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy